Brief: Cellectis Receives FDA Rmat Designation For Lasme-Cel, The First Allogeneic Car-T Therapy In A Pivotal Trial For Patients With R/R B-All
09/06/2026 21:39
BRIEF-Cellectis Receives FDA Rmat Designation For Lasme-Cel, The First Allogeneic Car-T Therapy In A Pivotal Trial For Patients With R/R B-All June 9 (Reuters) - Cellectis SA ALCLS.PA:
CELLECTIS RECEIVES FDA RMAT DESIGNATION FOR LASME-CEL, THE FIRST ALLOGENEIC CAR-T THERAPY IN A PIVOTAL TRIAL FOR PATIENTS WITH R/R B-ALL
CELLECTIS - FINAL PHASE 1 BALLI-1 DATA FOR LASME-CEL TO BE PRESENTED JUNE 13, 2026
Source text: ID:nGNXjHKtr
Further company coverage: ALCLS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cellectis SA
See all newsNASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:05 AM
Brief: Cellectis Receives FDA Rmat Designation For Lasme-Cel, The First Allogeneic Car-T Therapy In A Pivotal Trial For Patients With R/R B-All
Brief: Cema-Cel Pivotal Trial Interim Data Highlight Strength Of Cellectis’ Allogeneic Car-T Platform
France's Cellectis swings to net loss in Q4
Brief: Cellectis Q4 Operating Income USD -17.352 Million